22 results
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 Nov 20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
9:30am
vaccines don’t provide complete community protection and people also rely on therapies, our AT-301 nasal spray therapy should form an important and necessary
424B3
ATOS
Atossa Therapeutics Inc
7 Feb 20
Prospectus supplement
5:23pm
of transactions by a central bank or other public institutions of or within the international banking community;
the European Currency Unit both within
424B3
ATOS
Atossa Therapeutics Inc
27 Oct 17
Prospectus supplement
12:00am
community;
the European Currency Unit both within the European Monetary System and for the settlement of transactions by public institutions
424B5
zagpnaxlzq
27 Jan 14
Prospectus supplement for primary offering
12:00am
424B5
cyqgr2xkc9owziq3 92
23 Jan 14
Prospectus supplement for primary offering
12:00am
10-K
vy5ukyv1e5nrjzc5xm
28 Mar 13
Annual report
12:00am
8-K
EX-99.1
lg5h kdpu8h7xy85zsft
13 Mar 13
Atossa Genetics Announces National
12:00am
S-1/A
dhjslwjbj8p7 fhr0qx
23 Nov 10
IPO registration (amended)
12:00am